To develop an effective first-line treatment for CD5-positive DLBCL, several studies have examined treatments that combine dose-adjusted EPOCH-R, an improvement over conventional R-CHOP, with high-dose methotrexate therapy preventing central nervous system invasion; this research includes an ongoing institutional study (PEARL) in Japan [15]. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.